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Volumetric stratification 
of cT4 stage head 
and neck cancer
Advanced stage head and neck cancer 
(HNC) is known for generally unfavor-
able outcome with only ~40–50% 3-year 
overall survival [1, 2, 3]. Clinical T4 stage 
includes a wide range of tumor volumes. 
The lack of further nonsurgical subgroup-
ing of cT4 stage makes intercenter com-
parison of outcome results in irradiat-
ed cT4 patient cohorts difficult. The esti-
mation of operability (cT4a versus cT4b) 
is sometimes quite dependent of a sur-
geon’s individual opinion and experience. 
In addition, the in- or exclusion of very 
advanced cT4 any NM0 into curatively 
aimed treatment regimens remains quite 
subjective.
The aim of this analysis was to further 
stratify cT4 stage squamous cell HNC dis-
ease using volumetric staging. This was 
performed with the help of a formerly 
prospectively tested and published volu-
metric scoring system [4, 5, 6, 7]. Using 
this scoring system, we previously demon-
strated that volumetric staging was supe-
rior compared to the standard TN/AJCC 
systems regarding predictive power of dis-
ease control and survival of our irradiat-
ed cohorts.
Included in the presented analysis were 
all cT4 stage primary squamous cell can-
cer (SCC) HNC patients referred for de-
finitive radiation.
Methods
Between January 2002 and January 2013, a 
total of 201 cT4 stage SCC HNC patients 
were referred to our department. All were 
treated with curative intent with modulat-
ed radiotherapy ± chemotherapy. All pa-
tients were retrospectively stratified us-
ing a prospectively evaluated volumetric 
staging system. T4 lymphoepithelial na-
sopharynx tumors (n=13) and paranasal 
tumors (n=8) were excluded. The used 
staging system is based on three cut-offs 
(15/70/130 ml, see also previous publica-
tions [4, 5, 6, 7]) to stratify the total gross 
tumor volumes (tGTV: primary and nodal 
tumor volume), allowing a subdivision of 
cT4 stages into 4 prognostic subgroups [1–
15 ml (n=15), 16–70 ml (n=108), 71–130 ml 
(n=62), >130 ml (n=16)]. Overall survival 
(OS), disease-free survival (DFS), locore-
gional control (LRC), and distant metasta-
sis-free survival (DMFS) rates were calcu-
lated using Kaplan–Meier curves. Demo-
graphic data and tumor characteristics are 
listed in . Tab. 1.
All patients underwent modulated ra-
diation therapy using simultaneously in-
tegrated boost techniques [SIB-IMRT/
SIB-volumetric modulated arc therapy 
(SIB-VMAT)]. In 84%, concomitant cis-
platin chemotherapy (40 mg/m2/radia-
tion week) or cetuximab (loading dose 
400 mg/m2, followed by concomitant 
doses of 2250 mg/m2/radiation week) 
was administered. In 36 patients with 
very advanced disease of questionably 
curable stage, TPF (docetaxel, cis platin, 
5-fluorouracil)-based induction chemo-
therapy was given as a decision aid to add 
or not curatively intended radiation. The 
remaining 16% of patients were treated 
with radiation only because of age or sub-
stantial comorbidity.
All GTVs were contoured or reviewed 
by at least one of the authors on all rel-
evant axial computerized images with-
out using interpolation; in most cases the 
contouring was also reviewed by a third 
staff physician. In addition, the wide volu-
metric ranges (cut-offs 15/70/130 ml) ren-
der the system quite robust with respect 
to interindividual contouring differences. 
Volumetric three-dimensional measure-
ments (cm3) of contoured structures were 
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calculated by the Varian Treatment Plan-
ning System volume algorithm (Eclipse® 
External Beam Planning System, Ver-
sion 7.3.10 and PRO 8.9, AAA 8.9, Vari-
an Medical Systems). A detailed descrip-
tion of the applied SIB modulated tech-
niques and contouring of gross tumor vol-
ume (GTV) and planning target volumes 
(PTVs) has formerly been published [7]. 
In several patients with very large GTVs, 
dose compromises were performed de-
livering 66–68 Gy to the boost volume, 
while the 70 Gy dose volume was limited 
to the GTV.
Statistical analysis
Statistical calculations were performed 
using the statistics program implemented 
in StatView® (version 4.5; SAS Institute, 
Cary, NC, USA). Univariate analyses were 
performed with a Cox proportional haz-
ards regression model in StatView®. Actu-
arial survival data were calculated using 
Kaplan–Meier curves and log-rank tests 
implemented in StatView®. P values <0.05 
were considered statistically significant.
Results
Outcome prediction by 
volumetric scoring
Between January 2002 and January 2013, a 
total of 201 cT4 stage SCC HNC patients 
were curatively treated at our department. 
The mean/median follow-up was 31/23 
months (range 1–116 months). In all, 67% 
of all patients were alive at last follow-up, 
and 49% had no signs of disease. Of the 
33% of patients who had died, 24% died 
due to disease-related reasons. The 3-year 
OS, DFS, LRC, and DMFS rates of the en-
tire cohort were 63, 44, 48, and 77%, re-
spectively.
Volumetric staging revealed its po-
tential to prognostically statistical-
ly significantly divide the cT4 co-
hort into 4 volume subgroups 
(V1/2/3/4): OS: 90%/72%/58%/18%; 
DFS:  83%/50%/39%/10%;  LRC: 
8 1 % / 5 3 % / 4 7 % / 1 5 % ;  DM F S : 
93%/90%/70%/41%, all p<0.0001, 
(. Tab. 2, . Fig. 1).
Additional parameters 
with potential impact on 
disease control and OAS
The following parameters were tested in 
univariate analysis:
F  histopathological grading (grade 2 
versus 3, no grade 1 cases), not signif-
icant,
F  age (>/<70 years), not significant,
F  cT4a versus cT4b: in 63% of the cas-
es this differentiation was not indicat-
ed; most of the remaining cases were 
scored as cT4a (therefore statistically 
not evaluable),
F  nodal status (cN0 vs N1 vs N2a vs 
N2b vs N2c vs N3; cN0 vs N1–2b vs 
N2c vs N3; cN0 vs cN1–2 vs cN3), 
not significant,
F  systemic therapy: as the sample siz-
es of the subgroup with versus with-
out systemic therapy was unbalanced 
(84% vs 16%—not the same patients 
with respect to substantial comorbidi-
ty and age), and systemic therapy was 
not homogeneous, no reliable infor-
Tab. 2 Outcome according to volume subgroups (V1-4, using cut-off values of 
15/70/130 ml)
    3-year survival rates
    LRC DMFS DFS OAS
cT4 n (%) % % % %
V1 1–15 ml 15 (7%) 81 93 83 90
V2 16–
70 ml
108 (54%) 53 90 50 72
V3 71–
130 ml
62 (31%) 47 70 39 58
V4 >130 ml 16 (8%) 15 41 10 18
P value  <0.0001 <0.0001 <0.0001 <0.0001
LRC locoregional control rate, DMFS distant metastasis-free survival rate, DFS disease-free survival rate, OS 
overall survival rate.
Tab. 1 Patient and tumor characteristics
Parameters cT4
Patients (n) 201
Gender (female:male) 25%:75%
Mean age (range) 62 (38–91) years
Mean/median folllow-up (range) 31/23 (1–116) months
Histology Squamous cell carcinoma 201
Diagnosis Mesopharynx 116 (58%)
Hypopharynx 42 (21%)
Oral cavity 24 (12%)
Larynx 19 (9%)
N stage N0 43 (21%)
N1–2b 61 (30%)
N2c 88 (44%)
N3 9 (5%)
Total gross tumor volume 
(tGTV)
Mean Range 64 ml (7–216)
V1 1–15 ml 15 (7%)
V2 16–70 ml 108 (54%)
V3 71–130 ml 62 (31%)
V4 >30 ml 16 (8%)
Concomitant systemic 
therapy
None 31 (15%)
Cisplatin only 112 (56%)
Cetuximab only 25 (12%)
Cisplatin switched to cetux-
imab
33 (16%)
Induction chemotherapy 36 (17%)
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mation can be drawn from this analy-
sis, which, however, showed a signifi-
cant difference in favor of the com-
bined modality subgroup (p=0.2; OS 
65% vs 50% at 3 years).
Treatment tolerance
With respect to treatment tolerance, the 
following findings in 117 locoregionally 
controlled patients were stated as based 
on the last clinical visit: 16/117 patients ex-
perienced any late term grade 3/4 side ef-
fects (LENT-SOMA, 14%). Only 6/16 pa-
tients (38%; 3% of all patients) suffered 
from persistent late term sequelae (1× xe-
rostomia G3, 1× loss of taste G3, 1× chon-
dronecrosis, 1× dysphagia G3, 2× feeding 
tube dependence).
Discussion
Aim of this work was to assess the poten-
tial of volumetric stratification of our cT4 
SCC HNC cohort into different prognos-
tic subgroups. We found volumetric strati-
fication highly statistically significant in 
predicting outcome for different volume 
subgroups in the assessed cT4 HNC co-
hort. The volumetric system itself is con-
sidered robust with respect to interobserv-
er GTV contouring, as its cut offs values 
differ markedly (15 ml/70 ml/130 ml) [4, 
7]. The potential benefit of the assessed 
stratification lays in its more precise pre-
diction of disease control in irradiated cT4 
patient cohorts, and therefore more accu-
rate characterization of cT4 cohorts for in-
tercenter comparison purposes.
A weakness of this study is its retro-
spective stratification approach, which 
however applied a prospectively tested 
staging system [4, 5, 6, 7]. In addition, the 
assessed cohort includes different unbal-
anced tumor sites as well as unbalanced 
volume subgroups (. Tab. 1).
To our knowledge there are no  similar 
comparable volumetric staging analyses 
published. Most published volumetric fo-
cused outcome analyses were based on di-
chotomizing the GTV (i.e., using just one 
cut-off), (. Tab. 3, [4, 7, 8, 9, 10, 11, 12, 13, 
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 
26, 27, 28, 29, 30, 31, 32, 33, 34, 35]). Four 
[17, 18, 20, 25] of the 31 listed reports were 
based on two or three cut-off values, our 
Abstract · Zusammenfassung
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Abstract
Background. Locoregionally advanced stage 
head and neck cancer (HNC) is known for 
unfavorable outcome with only ~40–50% 
3-year overall survival (OS). Clinical T4 stage 
includes a wide range of tumor burden. The 
lack of further nonsurgical subgrouping of 
cT4 stage makes intercenter outcome of ir-
radiated cohorts difficult. Aim of this analy-
sis was to further stratify cT4 stage HNC using 
volumetric staging.
Material and methods. Between January 
2002 and January 2013, a total of 201 cT4 
stage squamous cell cancer (SCC) HNC pa-
tients referred to our center for curative de-
finitive radiation were consecutively irradi-
ated. Radiation was performed using modu-
lated techniques. Total gross tumor volumes 
(tGTV: primary + nodal tumor volume) of 
all patients have retrospectively been strati-
fied using a prospectively evaluated volumet-
ric staging system which bases on 3 cut-offs 
(15/70/130 ml), translating into 4 prognostic 
subgroups [V1: 1–15 ml (n=15), V2: 16–70 ml 
(108), V3: 71–130 ml (62), V4: >130 ml (16)]. 
OS, disease-free survival (DFS), locoregional 
control (LRC), and distant metastasis-free sur-
vival (DMFS) rates were calculated.
Results. The mean/median follow-up 
was 31/23 months (range 1–116 months). 
The 3-year OS, DFS, LRC, and DMFS rates 
of the entire cohort were 63, 44, 48, and 
77%, respectively. Volumetric  staging re-
vealed its potential to  prognostically 
statistically significantly divide the 
cT4 cohort into 4 volume subgroups 
(V1/2/3/4): OS: 90%/72%/58%/18%; 
DFS: 83%/50%/39%/10%;  LRC: 
 81%/53%/47%/15%; DMFS: 
93%/90%/70%/41%, all p<0.0001.
Conclusion. Volumetric staging allowed a 
highly statistically significant stratification of 
cT4 HNC stages into prognostic subgroups, 
which offers the chance of better  intercenter 
comparability of irradiated advanced stage 
HNC cohorts.
Keywords
Volumetric staging · cT4 stage tumors · Head 
and neck neoplasms · Neoplasm staging · 
Prognosis
Volumetrische Stratifizierung von 
Kopf-Hals-Tumoren im cT4-Stadium
Zusammenfassung
Hintergrund. Lokoregionär fortgeschrit-
tene Kopf-Hals-Tumoren (KHT) haben eine 
schlechte Prognose mit nur ~40–50% 
3-Jahres-Gesamtüberleben (GÜ). cT4-Stadi-
en beinhalten eine große Spanne von Tumor-
volumina. Das Fehlen einer weiteren nicht-
chirurgischen Unterteilung von cT4-Stadien 
macht den Vergleich der Resultate bestrahlter 
Kohorten aus verschiedenen Zentren schwie-
rig. Ziel unserer Arbeit war, cT4-Stadien bei 
definitiv bestrahlten KHT-Patienten mittels 
volumetrischem Staging zu stratifizieren.
Material und Methodik. Zwischen Januar 
2002 und Januar 2013 wurden uns 201 KHT-
Patienten mit einem Plattenepitelkarzinom 
im Stadium cT4 zur kurativen definitiven Ra-
diotherapie zugewiesen. Alle Patienten wur-
den mit modulierten Techniken bestrahlt. 
Das Gesamttumorvolumen (tGTV: Primärtu-
mor + Lymphknotenmetastasen) aller Patien-
ten wurde retrospektiv mittels eines prospek-
tiv getesteten volumetrischen Staging-Sys-
tems mit 3 Schnittwerten (15/70/130 ml) 
stratifiziert, was zu 4 prognostischen Sub-
gruppen führt [V1: 1–15 ml (n=15), V2: 16–
70 ml (n=108), V3: 71–130 ml (n=62), V4: 
>130 ml (n=16)]. GÜ, krankheitsfreies Über-
leben (KFÜ), lokoregionäre Kontrolle (LRK) 
und metastasenfreies Überleben (MFÜ) wur-
den berechnet.
Ergebnisse. Die mittlere/mediane Bobach-
tungszeit betrug 31/23 Monate (Spanne 
1–116 Monate). Das 3-Jahres-GÜ, -KFÜ, -LRK 
und -MFÜ der gesamten Kohorte betrug 
63, 44, 48 und 77%. Mittels volumetrischem 
Staging konnte die cT4-Kohorte in 4 statis-
tisch hochsignifikant unterschiedliche pro-
gnostische Untergruppen stratifiziert werden 
(jeweils V1/2/3/4): GÜ: 90%/72%/58%/18%; 
KFÜ: 83%/50%/39%/10%; LRK: 
81%/53%/47%/15%; MFÜ: 
93%/90%/70%/41%, alle p<0,0001.
Schlussfolgerung. Volumetrisches Stag-
ing erlaubte eine statistisch hochsignifikante 
Stratifizierung in prognostisch unterschied-
liche Untergruppen, was eine bessere Ver-
gleichbarkeit von Resultaten verschiede ner 
Zentren nach primärer intensitätsmodulier-
ter Strahlentherapie (IMRT) von cT4 KHT er-
möglichte.
Schlüsselwörter
Volumetrisches Staging · cT4-Tumorstadium · 
Kopf-Hals-Tumore · Tumorstaging · Prognose
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own system included. All but two analy-
ses showed significant difference in out-
come between larger vs smaller tumor 
volumes. Been et al. [34] failed to dem-
onstrate statistical significance between 
pGTV and locoregional outcome, per-
haps due to not considering the nodal tu-
mor volume which may significantly im-
pact locoregional outcome. Mendenhall et 
al. [8] found no outcome difference in tu-
mors of the hypopharynx/base of tongue/
posterior tonsillar pillar when using a cut 
off value of 6 ml. This cut-off may have 
been too low.
The data presented here are derived 
from a cohort treated with IMRT tech-
niques, with previous careful staging (in 
most cases using PET-CT) [36, 37].
Conclusion
Volumetric staging was shown to allow 
for highly statistically significantly strati-
fication of cT4 stage SCC HNC into differ-
ent prognostic subgroups, offering the 
option of better comparability of irradi-
ated advanced stage HNC cohorts.
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